18:20 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...
19:47 , Aug 20, 2018 |  BC Extra  |  Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Monday to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical candidates...
20:34 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

Debiopharm Group (Lausanne, Switzerland) completed enrollment of 96 patients with previously untreated, locally advanced squamous cell carcinoma of the head and neck (SCCHN) in the Phase II portion of a double-blind, placebo-controlled, French and Swiss...
21:09 , Dec 30, 2016 |  BC Week In Review  |  Company News

Threshold, NIH deal

Threshold and NIH’s NCI partnered to conduct preclinical testing assessing the biotech’s TH-3424 (AST-106) against T cell acute lymphoblastic leukemia (ALL) xenograft cell lines, which highly express aldo-keto reductase family 1 member C3 (AKR1C3) ....
14:16 , Nov 30, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Acute myelogenous leukemia (AML); lymphoma; multiple myeloma (MM) In vitro and mouse studies identified an MCL1 inhibitor that could help treat AML, lymphoma and MM. NMR-based fragment screening, chemical synthesis and optimization, and in...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

AT-406: Phase II started

Debiopharm began a double-blind Phase II trial of oral Debio 1143 plus carboplatin and paclitaxel. Debiopharm has exclusive, worldwide rights from Ascenta to develop and commercialize Debio 1143 (see BioCentury, Sept. 12, 2011). Ascenta Therapeutics...
02:08 , Aug 14, 2015 |  BC Extra  |  Financial News

Ascentage Pharma raises $15.5M in series A

Ascentage Pharma Group Corp. Ltd. (Hong Kong, China) raised $15.5 million in a series A round led by Oriza Seed Capital and YuanMing Capital. EFung Capital; BioVenture Capital; Grains Valley Venture Capital; and undisclosed investors...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Crystal structure of myeloid leukemia cell differentiation protein (MCL1)

Drug platforms TECHNOLOGY: Crystal structures Crystallographic studies on an MCL1 fusion protein could aid the structure-based design of MCL1-specific inhibitors. A fusion of maltose binding protein and MCL1 containing three mutations to enhance its crystal...
07:00 , Apr 30, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Myeloid leukemia cell differentiation protein (MCL1); B cell lymphoma 2 (BCL-2; BCL2); Bcl-XL

Cancer INDICATION: Cancer In vitro studies identified a tricyclic indole-based, selective inhibitor of MCL1 that could help treat cancer. Fragment-based drug design, chemical synthesis and in vitro testing of tricyclic 2-indole carboxylic acid analogs identified...
07:00 , Aug 4, 2014 |  BC Week In Review  |  Clinical News

AT-406: Phase I data

An open-label, U.S. Phase I trial in 29 AML patients showed that once-daily 100, 200, 300 or 400 mg oral Debio 1143 plus daunorubicin and cytarabine led to complete remission in 13 patients. Of those...